Acorda Therapeutics Inc. received a $1 million federal grant to study a potential treatment for heart failure, the company said Tuesday.
The grant is from the National Institute of Health's National Heart, Lung, and Blood Institute. Acorda expects to begin clinical testing of glial growth factor 2 as a treatment for heart failure in the next few months.
The company said the drug may be able to help promote the repair of heart tissue damage caused by disease or injury, which would improve heart function.
In afternoon trading, shares of Acorda Therapeutics Inc. declined 75 cents, or 2.4 percent, to $31.